Company intelligence / Profile preview

Ruizhen Pharmaceutical

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Ruizhen Pharmaceutical (Raygene) develops small molecule anti-tumor drugs, notably licensing RG001 (Tirapazamine, TATE), a hypoxia-activated prodrug targeting Topoisomerase II, combined with bispecific antibodies for advanced liver cancers.[7][11]

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Alphamab Oncology (co-development of KN046 + RG001 for HCC and CRC liver metastasis)

Beyond the preview

Go deeper on Ruizhen Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ruizhen Pharmaceutical.

Explore the full profile